An individual's journey to treat their severe hair loss condition using the medications Pyrilutamide and RU58841. They will provide regular updates on their progress.
The user discussed switching from RU58841 with Minoxidil to Finasteride due to cost, noting better physical feelings and hair growth with RU58841. They are considering returning to RU58841 and checking DHT levels after a month.
The conversation is about a user seeking help with hair regrowth treatments, specifically mentioning Setipiprant, Minoxidil, Finasteride, and RU58841. The user is trying to contact forum members for guidance on making and using these treatments.
PP405 shows promise in hair loss treatment, but stem cell therapy using adipose-derived stem cells and ATP also successfully reversed androgenetic alopecia in mice. Stem cell therapy is costly, and some doubt the effectiveness of PP405 based on press releases.
Stem cell-related treatments and drugs like RCGD423 and WAY are being tested for hair growth. Clinics are conducting tests on patients who haven't had previous treatments.
The conversation discusses the potential role of prolactin in hair loss and mentions treatments like HMI115, mucuna pruriens, Zinc, and B6 P5P for lowering prolactin levels. It also touches on the use of natural compounds and the lack of studies due to funding issues.
Tazarotene shows potential as a standalone treatment for hair regrowth by stimulating new hair follicle formation and promoting angiogenesis, similar to microneedling effects. It can be used topically without minoxidil, but users should start with a low concentration to avoid irritation.
Oleic acid and microneedling are being explored for hair regrowth, but results are mixed. Addressing DHT and fibrosis is crucial, with treatments like finasteride, minoxidil, and scalp massage also discussed.
Hair loss discussion includes treatments like Minoxidil, Finasteride, and RU58841. Users share experiences and support, mentioning that many people face hair thinning.
The conversation discusses using T3 (triiodothyronine) as a topical treatment for hair growth, with some users noting it showed promising results in studies but lacked follow-up. Users express interest in trying T3 due to its potential effectiveness compared to Minoxidil.
PP405 is a new hair loss treatment targeting dormant hair follicles, with ongoing trials. Some users consider stopping finasteride and minoxidil to join trials, while others doubt its effectiveness.
User shared progress on hair regrowth using Fin 1 mg/day for 4 years, Min 2x/day for 3 years, Estradiol 4mg/day, and Spironolactone 100mg/day for 3.5 months. They noted significant hairline recovery and advised against HRT for cis men due to feminizing effects.
A user shared their 9-month progress using RU58841 at 2% daily for hair regrowth, initially starting at 5% but reducing the dose due to early signs of gynecomastia, which has since mostly resolved. They achieved their goal of regrowing hair at the temples and hairline.
A user named "LordGeek101" shared their positive experience with hair regrowth after using 5mg of finasteride daily, 5% minoxidil twice daily, and hormone replacement therapy (HRT) for 8 months. The user is transgender (MTF) and mentioned that the larger dose of finasteride was recommended by their doctor for better chances of hair revival.
PP405 is seen as a potential breakthrough for converting vellus hairs to terminal hairs, with users expressing both hope and skepticism. It is compared to treatments like minoxidil and finasteride, with discussions on side effects and marketing concerns.
Hair loss due to DHT is causing distress, with Minoxidil, finasteride, and RU58841 being potential treatments. The conversation includes humor and frustration about the topic.
A user claims to have reversed baldness, possibly due to telogen effluvium recovery after weight loss. Others discuss the potential success of using GHK-Cu for hair regrowth.
Peptides, specifically GHK-Cu, are being considered for hair growth benefits, such as increasing blood flow to the scalp and preventing hair follicle shrinkage. A user reported starting GHK-Cu after hearing it made a friend's hair thicker.
Hair loss treatments include finasteride, minoxidil, and scalp exercises. Opinions vary on the effectiveness, with some attributing hair loss to muscle tension and inflammation, while others focus on genetics and DHT.
A 51-year-old on TRT plans to use steroids and is concerned about hair loss, considering topical treatments like Hair Rescue with RU58841 and finasteride, along with Nioxin shampoo. They are cautious about using oral DHT blockers due to potential interactions with steroids like Tren and Anavar.
The conversation is about a user seeking information on a clinical trial by Amplifica - Scube3 for Androgenetic Alopecia (AGA). The user is unsure if it's a formal phase 1 study.
Oral PTD-DBM was discussed as a potential hair loss treatment, but it was deemed ineffective in humans despite promising results in mice. The conversation concluded that trying it without VPA might be unwise.
The conversation discusses the delay in the PP405 Phase 2 study results, now expected by the end of 2025, and skepticism about research practices. There is also mention of optimism for Amplifica's AMP303 and a topical treatment in early testing.
ET-02, a new hair loss treatment, shows promising results with a 6-fold increase in hair count, potentially outperforming minoxidil by activating stem cells in hair follicles. Further trials are ongoing to confirm its efficacy and safety, with potential market release in the future.
A user is seeking a trusted supplier for RU58841 in the UK, expressing doubts about their current source, rudirect, and considering Anagenic and receptorchem. They are asking for recommendations for other suppliers.
Current hair loss treatments include finasteride, dutasteride, minoxidil, and derma rolling. New treatments like TDM-105795, GT20029, and others show promise but require more testing and time before approval.
PTD-DBM therapy for hair loss is being developed by Dr. Kang-Yell Choi, with human testing planned in South Korea. Some clinics in the U.S. offer PTD-DBM/valproic acid therapy, but it hasn't completed trials yet.